 |
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Feb 23, 2011
|
7.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb. 23, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in March:
Citi's 2011 Global Healthcare Conference
Wednesday, March 2, at 3:30 p.m. ET in New York
RBC Capital Markets' Healthcare Conference
Thursday, Ma...
|
|
MAP Pharmaceuticals Appoints Scott R. Ward as Chairman of the Board of Directors
Feb 18, 2011
|
9.4 KB |
|
| |
MOUNTAIN VIEW, Calif., Feb. 18, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Scott R. Ward as Chairman of its Board of Directors. Steven A. Elms, the incumbent Chairman and an original venture capital investor in the Company, will step down from the Board of Directors after over six years of servi...
|
|
Allergan and MAP Pharmaceuticals Announce Collaboration on LEVADEX™ Investigational Therapy for Acute Migraine
Jan 31, 2011
|
19.9 KB |
|
| |
IRVINE, Calif. and MOUNTAIN VIEW, Calif., January 31, 2011 - Allergan, Inc. (NYSE: AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced a collaboration within the United States for LEVADEX™, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adul...
|
|
MAP Pharmaceuticals to Host Conference Call at 8:30 A.M. Eastern Time Tomorrow to Discuss Partnering Plans for LEVADEX™
Jan 30, 2011
|
7.3 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 30, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it will hold a conference call at 8:30 a.m. Eastern Time tomorrow, Monday, January 31, to discuss partnering plans for LEVADEX™. LEVADEX is MAP Pharmaceuticals' novel, orally inhaled, migraine therapy that has completed Phase 3 clinic...
|
|
MAP Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
Jan 4, 2011
|
6.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the company will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 8:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the Investor Relations section of M...
|
|
MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial
Dec 21, 2010
|
10.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Dec. 21, 2010 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced completion of the LEVADEX™ open-label safety trial. The Company has now completed the final trial necessary to support a New Drug Application (NDA) for LEVADEX and plans to submit an NDA in the first half of 2011. LEVADEX is a n...
|
|
MAP Pharmaceuticals Announces Successful Results for LEVADEX(TM) Thorough QT Trial
Nov 8, 2010
|
10.7 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today reported successful results from a thorough QT trial of its investigational LEVADEX™ orally inhaled migraine therapy. The trial evaluated the potential of a supra-therapeutic dose to cause an increase in the QT interval. Results of the tri...
|
|
MAP Pharmaceuticals Reports Third Quarter of 2010 Financial Results
Nov 5, 2010
|
16.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 5, 2010 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2010.
Net loss for the quarter ended September 30, 2010 was $14.2 million, compared to net income of $19.3 million during the same period in 2009. Net loss for the firs...
|
|
MAP Pharmaceuticals to Present at Upcoming Investor Conferences
Nov 3, 2010
|
7.0 KB |
|
| |
MOUNTAIN VIEW, Calif., Nov. 3 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in November:
Credit Suisse 2010 Healthcare Conference
Wednesday, November 10, at 4:30 p.m. ET / 2:30 p.m. MT in Phoenix
Lazard Capital Markets 7th Annual Healthcare ...
|
|
MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX(TM) in FREEDOM-301 Trial
Oct 29, 2010
|
10.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 29, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX(TM) orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be...
|
|
MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
Oct 21, 2010
|
8.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 21, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Thomas P. McCracken as Vice President, Intellectual Property. Mr. McCracken will lead the company's intellectual property program in support of the potential commercialization of the company's lead ...
|
|
MAP Pharmaceuticals to Present Additional Data Analyses From LEVADEX(TM) FREEDOM-301 Trial at 2010 European Headache and Migraine Trust International Congress
Oct 20, 2010
|
10.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 20, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present nine analyses relating to its LEVADEX(TM) orally inhaled migraine therapy product candidate, including analysis from the FREEDOM-301 Phase 3 trial, at the 2010 European Headache and Migra...
|
|
MAP Pharmaceuticals Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
Oct 4, 2010
|
8.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Oct 04, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today the completion of its previously announced underwritten offering of 3,000,000 shares of its common stock, as well as 450,000 additional shares of its common stock pursuant to the full exercise of the over-allotment op...
|
|
MAP Pharmaceuticals, Inc. Announces Pricing of Underwritten Registered Offering of Common Stock
Sep 29, 2010
|
8.9 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 29, 2010 /PRNewswire via COMTEX News Network/ -- MOUNTAIN VIEW, Calif., Sept. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of its underwritten registered offering of 3,000,000 shares of its common stock at an offering price of $14.50 per share. Net offering proceeds, ...
|
|
MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX(TM) Clinical Program
Sep 8, 2010
|
11.6 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 08, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX(TM). In addition, the Company has completed patient treatment in a th...
|
|
MAP Pharmaceuticals Reports No Difference in Pulmonary Artery Pressure Between LEVADEX(TM) and Placebo in Pharmacodynamics Trial
Sep 8, 2010
|
10.5 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 08, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today reported results from a pharmacodynamics (PD) trial comparing the acute effects on pulmonary artery pressure of LEVADEX(TM), dihydroergotamine mesylate (DHE) administered intravenously (IV) and placebo. In the trial, there was...
|
|
MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
Sep 7, 2010
|
7.1 KB |
|
| |
MOUNTAIN VIEW, Calif., Sept 07, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following healthcare conferences in September:
Morgan Stanley Global Healthcare Conference
Tuesday, September 14, at 11:30 a.m. ET in New York
Stifel Nicolaus 2010 Healthca...
|
|
MAP Pharmaceuticals Reports Second Quarter of 2010 Financial Results
Aug 3, 2010
|
14.8 KB |
|
| |
MOUNTAIN VIEW, Calif., Aug 03, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2010.
The net loss for the quarter ended June 30, 2010 was $12.5 million, compared to $5.0 million during the same period in 2009. The net loss for the first si...
|
|
MAP Pharmaceuticals to Present at Upcoming Healthcare Conferences
Jul 27, 2010
|
7.0 KB |
|
| |
MOUNTAIN VIEW, Calif., July 27, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor events in August:
Wedbush Life Sciences MAC Best Ideas: Management Access
Conference
Tuesday, August 3, at 8:00 a.m. ET in New York, New...
|
|
MAP Pharmaceuticals Announces Results from LEVADEX Pharmacokinetics Trial in Smokers
Jul 13, 2010
|
11.2 KB |
|
| |
MOUNTAIN VIEW, Calif., July 13, 2010 /PRNewswire via COMTEX News Network/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX(TM) orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was ...
|
|
|
